Please login to the form below

Not currently logged in
Email:
Password:

Encap begins construction of encapsulation plant

Scottish drug delivery company Encap begins construction of a new plant in Scotland to meet increased demand for its contract encapsulation services

Scottish drug delivery company Encap has begun construction of a new plant in Scotland to meet increased demand for its contract encapsulation services.

Encap says it will invest GBP 3m (USD 6.1m) in the new production facility, which will increase manufacturing capacity by up to 60 per cent.

The new site should be operational by June 2008, added the company.

Encap specialises in formulating high-potency cytotoxic compounds, which it then encapsulates using three proprietary sustained-release technologies: DuoCap, LayerCap and Abusolve. The technologies control when and where in the body the drug will be released.

Encap says that liquid-fill encapsulation is one of the fastest growing sectors of the drug delivery market, increasing at an annual rate of 10 to 30 per cent. The burgeoning biologics market is also responsible for growth, as vulnerable small molecule and protein-based drugs are protected by encapsulation as they pass down the alimentary canal.

Encap's customer base includes small biotechs to large pharmaceutical companies looking to reformulate existing products to extend their lifecycle. Currently, Encap is partnering with an unnamed US pharma client for a generic product which will soon be submitted to the FDA for accreditation.

3rd September 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics